Plasmodium falciparum liver stage-expressed protein (PfLSP)

Plasmodium falciparum liver stage-expressed proteins (PfLSPs) represent a diverse group of antigens and functional proteins synthesized during the parasite's obligatory developmental phase within human hepatocytes. This stage, known as the pre-erythrocytic phase, is a critical bottleneck in the malaria life cycle where a small number of sporozoites transform and multiply into thousands of merozoites (Miller et al., 2002). Key proteins such as Liver Stage Antigen 1 (LSA-1) are expressed exclusively during this phase and are essential for the successful maturation of the parasite before it enters the bloodstream (Conway et al., 1992). These proteins are primary targets for vaccine development, such as the RTS,S and R21 vaccines, which aim to elicit antibodies and T-cell responses to block infection (RTS,S Clinical Trials Partnership, 2015). Additionally, prophylactic drugs like atovaquone and primaquine target the metabolic pathways and survival mechanisms of the parasite during its residence in the liver (Baird, 2019). Targeting PfLSPs is a strategic priority for achieving sterile immunity and preventing the clinical manifestations of malaria. However, the high degree of genetic polymorphism in some of these proteins poses a significant challenge for broad-spectrum vaccine efficacy (Neafsey et al., 2015).

Other names

Liver stage antigenLSAPre-erythrocytic antigenLiver-specific proteinPfLSA

Inhibition of hepatic schizogony and induction of host immune responses to prevent the transition of the parasite from the liver to the bloodstream.